☆ 4.3 Review

Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis

JOURNAL OF ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Mark M. Awad et al.

Summary: First-line pembrolizumab plus pemetrexed-carboplatin showed continued improved response and survival compared to chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. No new safety signals were observed with longer follow-up.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

H. Gogas et al.

Summary: The combination therapy of MEK inhibitors and immune checkpoint inhibitors did not show improved progression-free survival compared to monotherapy with pembrolizumab in patients with previously untreated BRAF(V600) wild-type advanced melanoma.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study

Yi-Long Wu et al.

Summary: In Chinese patients with locally advanced/metastatic NSCLC, pembrolizumab demonstrated improved overall survival and lower occurrence of grade 3 to 5 treatment-related adverse events compared to chemotherapy, supporting its potential as a first-line treatment option.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen Liu et al.

Summary: IMpower133 trial showed that adding atezolizumab to CP/ET for first-line treatment of ES-SCLC significantly improved patients' overall survival. Atezolizumab demonstrated potential efficacy in treating ES-SCLC.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Martin Reck et al.

Summary: The study demonstrated that in treatment-naive patients with advanced NSCLC, nivolumab plus ipilimumab showed delayed deterioration and numerical improvement in symptoms and health-related quality of life compared to chemotherapy.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

Add to Collection

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Critical Care Medicine

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou et al.

Summary: The study showed a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus chemotherapy compared to chemotherapy alone, making it a promising first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations, with further long-term outcomes and confirmatory testing still ongoing.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Oncology

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

A. Brufsky et al.

Summary: The study evaluated the effectiveness of using cobimetinib plus chemotherapy, with or without the programmed death-ligand 1 inhibitor atezolizumab, in patients with locally advanced or mTNBC. The results showed that the addition of cobimetinib to paclitaxel did not significantly increase progression-free survival or objective response rate, but demonstrated potential activity in this difficult-to-treat population.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell et al.

Summary: The study evaluated the efficacy and safety of nivolumab in patients with pleural or peritoneal malignant mesothelioma who had progressed following platinum-based chemotherapy. Nivolumab showed improved progression-free survival and overall survival compared to placebo in these patients, with manageable treatment-related adverse events. The results suggest that nivolumab might be a beneficial treatment for patients with malignant mesothelioma who have progressed on first-line therapy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Taofeek K. Owonikoko et al.

Summary: Maintenance therapy with nivolumab plus ipilimumab did not prolong overall survival (OS) for patients with extensive-disease small-cell lung cancer (ED-SCLC) who did not progress on first-line chemotherapy. However, there may be a benefit of nivolumab plus ipilimumab in patients with a tumor mutational burden of >= 13 mutations per megabase. The rates of grade 3-4 treatment-related adverse events were highest in the nivolumab plus ipilimumab group.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer et al.

LANCET (2021)

Add to Collection

Article Oncology

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer et al.

Summary: Pembrolizumab did not significantly improve overall survival in patients with previously treated metastatic triple-negative breast cancer versus chemotherapy, indicating potential for further research in specific patient subpopulations and combination therapy for this disease.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt et al.

Summary: IMvigor010 is the largest adjuvant study evaluating a checkpoint inhibitor in muscle-invasive urothelial carcinoma. The trial did not show improved disease-free survival with atezolizumab compared to observation. Atezolizumab was generally well tolerated, but higher rates of adverse events leading to discontinuation were reported compared to previous studies on metastatic urothelial carcinoma.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

D. Rodriguez-Abreu et al.

Summary: Pembrolizumab plus pemetrexed-platinum continues to demonstrate improved efficacy outcomes compared to placebo plus pemetrexed-platinum, with manageable toxicity, supporting its first-line use in previously untreated metastatic nonsquamous non-small-cell lung cancer patients.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore et al.

Summary: The study evaluated the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody atezolizumab to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer, showing a significant progression-free survival advantage in the PD-L1-positive population. However, no significant overall survival benefit was observed from atezolizumab in the interim analysis. The most common grade 3 or 4 adverse events were neutropenia, hypertension, and anemia.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Nancy Y Lee et al.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly et al.

Summary: In patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab significantly improved disease-free survival compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Oncology

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

L. A. Emens et al.

Summary: The study showed that although A + nP for first-line treatment of triple-negative breast cancer did not significantly improve overall survival in the overall population, clinically meaningful benefits were observed in patients with PD-L1 expression on tumor infiltrating immune cells. The combination therapy remained safe and tolerable with longer follow-up.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

D. Miles et al.

Summary: Combining atezolizumab with paclitaxel did not improve PFS or OS in PD-L1-positive aTNBC patients, although it showed some advantage in unconfirmed best overall response rate and duration of response.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

S. Sugawara et al.

Summary: This international study evaluated nivolumab with bevacizumab and chemotherapy as a first-line treatment for nonsquamous NSCLC, showing significantly longer progression-free survival and higher objective response rates in the nivolumab group compared to the placebo group in the interim analysis. The incidence of severe treatment-related adverse events was comparable between the two groups.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Lajos Pusztai et al.

Summary: The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib with standard paclitaxel neoadjuvant chemotherapy showed superior efficacy in treating HER2-negative breast cancer, especially in a subset of high-risk HR-positive/HER2-negative patients.

CANCER CELL (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial

Huiyan Luo et al.

Summary: The addition of camrelizumab to chemotherapy significantly improved overall survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma. This treatment strategy could enhance the overall survival rate of patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

Add to Collection

Article Oncology

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles et al.

Summary: The study examined the outcomes of using pembrolizumab alone or combined with chemotherapy as first-line treatment for advanced urothelial carcinoma, and found that the addition of pembrolizumab to platinum-based chemotherapy did not significantly improve efficacy. Safety was assessed and the study concluded that this combination treatment should not be widely adopted for this type of cancer.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Eric Pujade-Lauraine et al.

Summary: This study compared the efficacy of avelumab alone, avelumab plus PLD, and PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer. The results showed that neither avelumab plus PLD nor avelumab alone significantly improved progression-free survival or overall survival compared to PLD.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Xiaofei Zhu et al.

Summary: This study aimed to evaluate the efficacy of SBRT plus pembrolizumab and trametinib in patients with postoperative locally recurrent pancreatic cancer. Among 198 patients, the median overall survival was significantly longer in the SBRT plus pembrolizumab and trametinib group compared to the SBRT plus gemcitabine group. The most common adverse effects were mild to moderate in severity.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

Bradley J. Monk et al.

Summary: The JAVELIN Ovarian 100 trial compared the efficacy of avelumab in combination with chemotherapy followed by avelumab maintenance, avelumab plus chemotherapy followed by avelumab maintenance, or chemotherapy alone in treatment-naive epithelial ovarian cancer patients. Results showed that avelumab did not demonstrate significant benefits in frontline treatment, suggesting the need for alternative treatment regimens to improve outcomes in advanced epithelial ovarian cancer patients.

LANCET ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai et al.

Summary: The study is a double-blind phase 3 trial that shows the combination of toripalimab with GP chemotherapy for RM-NPC patients provides a superior PFS compared to GP alone. Most adverse events were similar between the two arms, but immune-related AEs were more frequent in the toripalimab arm.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

N. Colombo et al.

Summary: Adding pembrolizumab to chemotherapy significantly improves progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer when compared to placebo. Anemia and neutropenia are the most common grade 3 to 5 adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

D. F. Bajorin et al.

Summary: In a trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab showed longer disease-free survival compared to placebo, especially among patients with a PD-L1 expression level of 1% or more, despite an increase in treatment-related adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Oncology

Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis

Yuan Tian et al.

Summary: PD-1/PD-L1 inhibitors have a lower risk of death compared to chemotherapy in clinical trials. In addition to death, they also have better safety profiles when considering treatment-related adverse events, discontinuation of therapy, and grades 3-5 adverse events.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis

Yuan Tian et al.

Summary: The updated meta-analysis showed that PD-1/PD-L1 inhibitors significantly increase the risk of thyroid dysfunction in cancer patients. Compared with chemotherapy, these inhibitors are particularly prone to causing hypothyroidism, especially when combined with other treatments.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

A review of cancer immunotherapy toxicity

Lucy Boyce Kennedy et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Oncology

The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

Yuan Tian et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Shirish Gadgeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer

Zia Khan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Oncology

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert Jotte et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer et al.

LANCET (2020)

Add to Collection

Article Oncology

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf et al.

LANCET (2020)

Add to Collection

Article Oncology

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A Emens et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer et al.

NATURE MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Kohei Shitara et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T. Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Antoni Ribas et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Oncology

Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis

Hongmei Liu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi-Long Wu et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).

Nuzzo Pier Vitale et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini et al.

LANCET (2019)

Add to Collection

Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Fiamma Berner et al.

JAMA ONCOLOGY (2019)

Add to Collection

Editorial Material Oncology

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Jordi Remon et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Ryan J. Sullivan et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Review Oncology

The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis

Zhihua Si et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Letter Oncology

Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Focusing on Organ-Specific irAEs and the Critical Role of Steroids

Xu Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

Add to Collection

Article Oncology

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert Motzer et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E. W. Cohen et al.

LANCET (2019)

Add to Collection

Article Oncology

Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Toyoaki Hida et al.

CLINICAL LUNG CANCER (2018)

Add to Collection

Editorial Material Medicine, General & Internal

Odds Ratios-Current Best Practice and Use

Edward C. Norton et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Medicine, General & Internal

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Thomas Powles et al.

LANCET (2018)

Add to Collection

Editorial Material Oncology

IMMUNOTHERAPY Cancer immunotherapy and the value of cure

Joseph C. Del Paggio

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M. M. Eggermont et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Frank Stephen Hodi et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Dermatology

Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy

Vincent Sibaud

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon-Koo Kang et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J. Bellmunt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst et al.

LANCET (2016)

Add to Collection

Article Oncology

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott J. Antonia et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

R. L. Ferris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Oncology

Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study

Eric Van Cutsem et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Review Oncology

The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis

Y. Balagula et al.

ANNALS OF ONCOLOGY (2011)

Add to Collection

Article Psychology, Multidisciplinary

Assessing heterogeneity in meta-analysis:: Q statistic or I2 index?

Tania B. Huedo-Medina et al.

PSYCHOLOGICAL METHODS (2006)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.